Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Veru ( (VERU) ) has provided an update.
On October 30, 2025, Veru Inc. entered into an underwriting agreement with Canaccord Genuity LLC for a public offering of 8,400,000 shares of its common stock, along with Series A and B warrants, expected to raise approximately $23.4 million. The proceeds will primarily fund the development of enobosarm, focusing on the Phase 2b PLATEAU clinical study, and for general corporate purposes. The offering is expected to close on or about October 31, 2025, subject to customary conditions, and aims to strategically position Veru in the biopharmaceutical market by advancing its clinical pipeline.
The most recent analyst rating on (VERU) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Veru stock, see the VERU Stock Forecast page.
Spark’s Take on VERU Stock
According to Spark, TipRanks’ AI Analyst, VERU is a Neutral.
Veru’s overall stock score is primarily impacted by its weak financial performance and valuation concerns. While technical analysis provides some neutral signals, the company’s ongoing financial losses and cash flow issues overshadow potential clinical advancements.
To see Spark’s full report on VERU stock, click here.
More about Veru
Veru Inc. is a late clinical stage biopharmaceutical company focused on developing innovative medicines for the treatment of cardiometabolic and inflammatory diseases.
Average Trading Volume: 166,321
Technical Sentiment Signal: Sell
Current Market Cap: $51.3M
Learn more about VERU stock on TipRanks’ Stock Analysis page.